ConductScience.org, home

Paper41228344

High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).

Arad A and 13 others. Cancers (Basel), 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T). Papers, record 41228344. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41228344

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).
PubMed
Journal
Cancers (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-11-16
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Arad AArielahttps://orcid.org/0000-0001-8504-8641
2Katz MMaya
3Lebel EEyalhttps://orcid.org/0000-0001-5215-7278
4Kalish YYosef
5Assayag MMiri
6Avni BBatiahttps://orcid.org/0000-0001-8516-2751
7Elias SShlomo
8Grisariu SSigal
9Shai EEla
10Kfir-Erenfeld SShlomit
11Asherie NNathaliehttps://orcid.org/0000-0002-5541-1208
12Gatt MEMoshe Ehttps://orcid.org/0000-0002-9426-4482
13Stepensky PPolina
14Zimran EEranhttps://orcid.org/0000-0002-5483-5180

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139653116Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.J Clin Oncol2025https://conductscience.org/library/papers/39653116PubMed
227412889T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Blood2016https://conductscience.org/library/papers/27412889PubMed
337176053Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.Int J Mol Sci2023https://conductscience.org/library/papers/37176053PubMed
433608658CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial.Bone Marrow Transplant2021https://conductscience.org/library/papers/33608658PubMed
530592986ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/30592986PubMed
638821074
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lancet Oncol2024https://conductscience.org/library/papers/38821074PubMed
737471687Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.J Clin Oncol2023https://conductscience.org/library/papers/37471687PubMed
840216223Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.J Thromb Haemost2025https://conductscience.org/library/papers/40216223PubMed
934595461The Many Faces of Cytokine Release Syndrome-Related Coagulopathy.Clin Hematol Int2021https://conductscience.org/library/papers/34595461PubMed
1036906275Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.Transplant Cell Ther2023https://conductscience.org/library/papers/36906275PubMed
1128928126Chimeric antigen receptor T-cell therapies for multiple myeloma.Blood2017https://conductscience.org/library/papers/28928126PubMed
1232683907Fibrinogen Diagnostics in Major Hemorrhage.Crit Rev Anal Chem2022https://conductscience.org/library/papers/32683907PubMed
1331786240Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies.Biol Blood Marrow Transplant2020https://conductscience.org/library/papers/31786240PubMed
1434521106Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.Blood Adv2021https://conductscience.org/library/papers/34521106PubMed
1528924019Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.Blood2017https://conductscience.org/library/papers/28924019PubMed
1639521987New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.Exp Hematol Oncol2024https://conductscience.org/library/papers/39521987PubMed
1732877523Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma.Blood Adv2020https://conductscience.org/library/papers/32877523PubMed
1831378662A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.Lancet Haematol2019https://conductscience.org/library/papers/31378662PubMed
1929812997T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.J Clin Oncol2018https://conductscience.org/library/papers/29812997PubMed
2022160384B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.Blood2012https://conductscience.org/library/papers/22160384PubMed

See all 31 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FGB2244PubTator's text mininghttps://conductscience.org/library/genes/2244

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41228344

GET https://conductscience.org/api/papers/v1/41228344/references?page=2